 SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer today announced that the U.S. Food Drug Administration FDA has cleared an Investigational New Drug IND application to study ALLO-715, Allogenes investigational BCMA AlloCAR T therapy, in combination with nirogacestat, SpringWorks Therapeutics investigational gamma secretase inhibitor GSI, in patients with relapsed or refractory multiple myeloma. This combination is part of the companys multi-pronged strategy to develop a treatment for multiple myeloma and will be deployed in the ongoing UNIVERSAL trial. Enrollment in this cohort is expected to begin in the first quarter of 2021. 